Sermorelin vs MK-677

Overview

Sermorelin and MK-677 (ibutamoren) both stimulate growth hormone release but through different receptors and with different pharmacokinetics. Sermorelin is a GHRH analog requiring injection, while MK-677 is an oral ghrelin mimetic with a long half-life. Sermorelin was previously FDA-approved; MK-677 was never approved despite extensive trials.

Key Facts

Aspect	Sermorelin	MK-677
Class	GHRH analog	GH secretagogue
Type	Peptide (injectable)	Small molecule (oral)
Target	GHRH receptor	GHS-R1a (ghrelin receptor)
FDA Status	Previously approved	Never approved
Half-life	~10-20 minutes	~24 hours

Mechanism Comparison

Aspect	Sermorelin	MK-677
Receptor	GHRH-R	GHS-R1a
Pathway	GHRH signaling	Ghrelin signaling
GH Pattern	Pulsatile (physiological)	Sustained elevation
IGF-1 Effect	Increases (moderate)	Increases significantly
Half-life Impact	Short action	Long-lasting

Key Mechanistic Differences

Sermorelin:

• Mimics natural GHRH
• Creates normal GH pulsatility
• Short half-life = transient effect
• More physiological pattern

MK-677:

• Mimics ghrelin signaling
• Long half-life = sustained GH/IGF-1
• 24-hour oral dosing
• Less physiological, more continuous

Evidence Comparison

Aspect	Sermorelin	MK-677
Human Trials	Historical (FDA approved)	Extensive (never approved)
Regulatory Review	Passed (then discontinued)	Failed to achieve approval
Long-term Data	Limited recent	Substantial trial data
Publication Quality	Moderate	Moderate-high

Why MK-677 Never Got Approved

Despite many trials in various populations:

• Hip fracture recovery: No functional benefit
• Obesity: Appetite increase counterproductive
• Elderly: No clear therapeutic window
• GH deficiency: Alternatives exist
• Metabolic concerns (glucose, appetite)

GH Release Comparison

Parameter	Sermorelin	MK-677
GH Pattern	Pulsatile	Elevated baseline
IGF-1 Increase	Moderate	Significant (~50-100%)
Duration	2-3 hours	24 hours
Physiological	More	Less

Side Effect Comparison

Sermorelin

Effect	Frequency	Notes
Injection site reactions	Common	Local redness
Flushing	Occasional	Facial warmth
Headache	Occasional	Usually mild
Antibody formation	Possible	May reduce efficacy

MK-677

Effect	Frequency	Notes
Increased appetite	Very common	Major limitation
Water retention	Very common	Edema, bloating
Lethargy	Common	Morning fatigue
Hyperglycemia	Common	Metabolic concern
Muscle pain	Common	GH-related
Numbness/tingling	Occasional	GH-related

Metabolic Impact

Effect	Sermorelin	MK-677
Appetite	Minimal	Strongly increases
Glucose tolerance	Minimal impact	Worsens
Insulin sensitivity	Preserved	Decreases
Water retention	Mild	Significant
Body composition	Favorable trend	Complicated by appetite

MK-677’s metabolic effects often counteract potential benefits.

Administration

Aspect	Sermorelin	MK-677
Route	Subcutaneous injection	Oral (tablet/liquid)
Convenience	Injection required	Oral (easy)

Availability and Quality

Factor	Sermorelin	MK-677
US Availability	Compounding pharmacies	Research chemical
Prescription Required	Yes	No (unregulated)
Quality Control	Variable (compounded)	None
Manufacturing	Compounding pharmacies	Unknown sources
WADA Status	Prohibited	Prohibited

Cost Comparison

Factor	Sermorelin	MK-677
Approximate Cost	$200-400/month	Variable
Insurance	Rarely covered	Never covered
Quality Assurance	Compounding standards	None

Key Differences

Factor	Sermorelin	MK-677
Administration	Injectable	Oral
Half-life	Short (~15 min)	Long (~24 hrs)
GH Pattern	Pulsatile	Sustained
Appetite Effect	Minimal	Strong increase
Glucose Effect	Minimal	Worsens
Regulatory History	Was approved	Never approved
Quality	Variable (compounded)	Unknown

Summary

• Sermorelin is a GHRH analog that produces physiological GH pulsatility but requires injection
• MK-677 is an oral option with convenient dosing but significant metabolic side effects
• MK-677’s appetite increase and glucose effects are major limitations
• Sermorelin creates more natural GH patterns; MK-677 causes sustained elevation
• MK-677 was never approved despite extensive trials
• Both are prohibited in sport
• Quality concerns exist for both (compounding vs research chemical)

---

This comparison is for educational purposes only. Sermorelin requires prescription (compounded). MK-677 is not approved for human use. Consult a healthcare provider for medical decisions.